Liraglutide vs Dulaglutide
Liraglutide and dulaglutide represent two fundamentally different approaches to extending the half-life of native GLP-1. Liraglutide employs non-covalent albumin binding via fatty acylation, while dulaglutide uses covalent fusion to immunoglobulin Fc. Both achieve once-weekly or once-daily dosing through distinct pharmacokinetic mechanisms.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Liraglutide
Section titled “Liraglutide”Liraglutide is a 31-amino acid GLP-1 analogue with 94% sequence homology to native GLP-1(7-37). Two modifications confer extended half-life: (1) Aib substitution at position 8 blocks DPP-4 cleavage, and (2) a C-16 palmitoyl fatty acyl chain is attached to Lys26 via a glutamic acid spacer. The hydrophobic acyl chain promotes non-covalent self-association at injection sites and reversible albumin binding in plasma, extending the half-life to approximately 13 hours.
Liraglutide activates GLP-1R with an EC₅₀ of ~0.2 nM, producing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction.
Dulaglutide
Section titled “Dulaglutide”Dulaglutide is a 39-amino acid GLP-1 analogue fused to human IgG4 Fc via a small peptide linker. The GLP-1 component contains a single amino acid substitution (Gly→Ala at position 8) for DPP-4 resistance. The Fc fusion confers neonatal Fc receptor (FcRn)-mediated recycling, extending the half-life to approximately 90 hours (3.75 days).
Dulaglutide activates GLP-1R with an EC₅₀ of ~0.1 nM. The Fc fusion does not confer complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity due to the IgG4 isotype.
Comparison Table
Section titled “Comparison Table”| Property | Liraglutide | Dulaglutide |
|---|---|---|
| Amino acid count | 31 | 39 (GLP-1) + Fc |
| MW (Da) | 3,751 | 63,700 |
| Conjugation strategy | Fatty acylation (C-16 palmitoyl) | Fc fusion (IgG4) |
| Half-life | ~13 hrs | ~90 hrs |
| Dosing frequency | Once daily | Once weekly |
| GLP-1R EC₅₀ | ~0.2 nM | ~0.1 nM |
| Bioavailability | ~55% | ~65% |
| Albumin binding | Yes (reversible) | N/A (FcRn recycling) |
| DPP-4 resistance | Aib at position 8 | Ala at position 8 |
Pharmacokinetics
Section titled “Pharmacokinetics”The half-life difference reflects fundamentally different conjugation mechanisms. Liraglutide’s 13-hour half-life arises from albumin binding and self-association, producing a peak-to-trough ratio of approximately 2:1 at steady state. Dulaglutide’s 90-hour half-life derives from FcRn-mediated recycling — the same mechanism that maintains endogenous IgG at high plasma concentrations.
Dulaglutide achieves steady state after 2–3 weeks of once-weekly dosing, with peak-to-trough ratios of approximately 1.5:1. Liraglutide reaches steady state within 2–3 days of daily dosing.
Efficacy Data
Section titled “Efficacy Data”HbA1c Reduction
Section titled “HbA1c Reduction”| Trial | Liraglutide | Dulaglutide |
|---|---|---|
| AWARD-1 vs placebo | −1.0 to −1.3% (1.8 mg) | −1.2 to −1.5% (1.5 mg) |
| AWARD-1 vs exenatide ER | Superior | — |
| LEAD-6 vs exenatide BID | −1.0% (1.8 mg) | — |
| Duration | 26–52 weeks | 26–52 weeks |
Both agents produce clinically meaningful HbA1c reductions. Dulaglutide 1.5 mg achieves slightly greater reductions than liraglutide 1.8 mg in cross-trial comparisons, though direct head-to-head data are limited.
Weight Loss
Section titled “Weight Loss”| Agent | Dose | Weight Change |
|---|---|---|
| Liraglutide | 1.8 mg daily | −3.0 to −5.0 kg |
| Liraglutide | 3.0 mg daily (obesity) | −5.0 to −8.0 kg |
| Dulaglutide | 1.5 mg weekly | −1.5 to −3.0 kg |
| Dulaglutide | 3.0 mg weekly | −2.0 to −4.0 kg |
Liraglutide produces greater weight loss, particularly at the 3.0 mg obesity dose. This difference may relate to more sustained central GLP-1R exposure with daily dosing and the additional appetite-suppressive effects of higher peak concentrations.
Side Effect Profiles
Section titled “Side Effect Profiles”| Side Effect | Liraglutide | Dulaglutide |
|---|---|---|
| Nausea | 25–44% | 12–18% |
| Diarrhea | 12–30% | 10–15% |
| Vomiting | 8–24% | 5–8% |
| Decreased appetite | 10–20% | 5–12% |
| Injection site reactions | 1–7% | 2–5% |
| Antibody formation | 10–15% | 3–8% |
Liraglutide produces more GI side effects, consistent with higher peak concentrations. Dulaglutide’s larger molecular size may reduce GI exposure, resulting in improved GI tolerability. Anti-drug antibody formation is more common with liraglutide but does not appear to compromise efficacy.
Immunogenicity Considerations
Section titled “Immunogenicity Considerations”Dulaglutide’s Fc fusion raises unique immunogenicity questions. The IgG4 Fc domain is inherently less immunogenic than IgG1 due to reduced FcRn and FcγR binding. Anti-drug antibodies develop in 3–8% of dulaglutide-treated patients, compared to 10–15% with liraglutide. Cross-reactivity with endogenous GLP-1 is minimal for both agents.
Cost and Access
Section titled “Cost and Access”| Factor | Liraglutide | Dulaglutide |
|---|---|---|
| Brand names | Victoza (T2D), Saxenda (obesity) | Trulicity (T2D) |
| List price (monthly) | ~$850–1,200 | ~$900–1,000 |
| Insurance coverage | Broadly covered | Broadly covered |
| Injection frequency | Once daily | Once weekly |
| Pen device | Pen (3 doses) | Single-use pen |
Weekly dulaglutide dosing provides an adherence advantage. However, liraglutide’s availability in higher doses for obesity (Saxenda 3.0 mg) gives it a unique indication that dulaglutide lacks.
When to Choose Which
Section titled “When to Choose Which”Liraglutide may be preferred when:
- Obesity is the primary indication (3.0 mg dose)
- More gradual dose titration is desired
- Cost or insurance favors Victoza/Saxenda
- Higher weight loss is the therapeutic goal
Dulaglutide may be preferred when:
- Once-weekly dosing improves adherence
- Better GI tolerability is needed
- Patient preference for fewer injections
- Established T2D management without obesity focus
References
Section titled “References”- Nauck MA, et al. “Efficacy and safety of liraglutide versus placebo in type 2 diabetes (LEAD-6).” Diabetes Care 2009;32:84-90.
- Wysham C, et al. “Efficacy and safety of dulaglutide in the AWARD-1 trial.” Lancet 2014;384:53-60.
- Buse JB, et al. “Dulaglutide versus exenatide once weekly in patients with type 2 diabetes (AWARD-1).” Lancet 2014;384:53-60.
- Wilding JPH, et al. “Liraglutide 3.0 mg for obesity (SCALE).” NEJM 2015;373:11-22.
- Umpierrez G, et al. “Dulaglutide versus insulin glargine in patients with type 2 diabetes (AWARD-4).” Lancet Diabetes Endocrinol 2015;3:618-627.